Skip to main content

Table 1 Distribution of TILs according to patient and tumour characteristics (n = 477)

From: Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up

Variable

TIL low (< 10%)

n (%)

TIL intermediate (10–49%)

n (%)

TIL high (≥ 50%)

n (%)

P valuea

Age (years)

0.02

 < 40

41 (44)

32 (34)

21 (22)

 

 ≥ 40

207 (54)

125 (33)

51 (13)

 

Nodal status

0.34

 0

65 (47)

42 (31)

30 (22)

 

 1–3

137 (59)

66 (28)

30 (13)

 

 ≥ 4

46 (44)

47 (45)

12 (11)

 

 Missing

0

2

0

 

Tumour size (mm)

0.06

 ≤ 20

97 (57)

52 (31)

20 (12)

 

 > 20

151 (49)

104 (34)

52 (17)

 

 Missing

0

1

0

 

Histological grade (NHG)

< 0.001

 1

44 (86)

7 (14)

0

 

 2

135 (70)

52 (27)

5 (3)

 

 3

56 (27)

91 (43)

64 (30)

 

 Missing

13

7

3

 

ER

< 0.001

 Negative

45 (29)

63 (40)

48 (31)

 

 Positive

203 (63)

94 (29)

24 (8)

 

PR

< 0.001

 Negative

41 (27)

63 (41)

50 (33)

 

 Positive

206 (64)

93 (29)

21 (7)

 

 Missing

1

1

1

 

HER2

0.001

 Negative

205 (56)

109 (30)

50 (14)

 

 Positive

22 (33)

28 (42)

16 (24)

 

 Missing

21

20

6

 

LVI

0.87

 Absent

140 (54)

76 (30)

42 (16)

 

 Present

108 (50)

81 (37)

28 (13)

 

 Missing

0

0

2

 

Ki67 (%)

< 0.001

 ≤ 10

126 (71)

40 (23)

12 (7)

 

 11–25

60 (56)

33 (31)

14 (13)

 

 ≥ 26

22 (20)

53 (48)

36 (32)

 

 Missing

40

31

10

 

Histopathological type

< 0.001

 Ductal/NST

200 (52)

134 (35)

48 (13)

 

 Lobular

29 (81)

7 (19)

0

 

 Medullary

0

3 (13)

20 (87)

 

 Other

9 (75)

2 (17)

1 (8)

 

 Missing

10

11

3

 

Subtype

< 0.001

 ER+/HER2−

176 (69)

65 (25)

16 (6)

 

 HER2+

22 (33)

28 (42)

16 (24)

 

 TNBC

20 (21)

42 (44)

33 (35)

 

 Missing

30

22

7

 

Total

248 (52)

157 (33)

72 (15)

 
  1. a Chi2 test for trend, except for the non-ordinal variables histopathological type and subtype, when conventional chi2 test was used
  2. Abbreviations: ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, LVI lymphovascular invasion, NST no special type, NHG Nottingham histological grade, PR progesterone receptor, TILs tumour-infiltrating lymphocytes, TNBC triple-negative breast cancer